Tagged with

Lundbeck China Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position of General Manager for Lundbeck China. Lundbeck originally sold its products in China exclusively through partners for several years. What…

polski holding farmaceutyczny (PHF) Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was to privatise the three entities. You joined in March 2008, at a time when, if I may say, major steps…

Polpharma SA For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to the benefit of MNCs. How has the arrival of GSK, Teva or Sandoz, altered the playing field for the company…

Teva Italy Mr. Medda, Teva’s Italian history is relatively young, could you describe the main facts that describe Teva presence in Italy? Teva Italia was founded in 1996 and is currently the leading generic pharmaceutical company in Italy. So, the company has experienced rapid growth in the emerging generic market over the…

Servier Poland Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in Romania, Russia, and Bulgaria, but also Vietnam, what is unique here? What is there in Poland that is attracting the…

Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…

Torrex Chiesi Poland Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market size was always very attractive for all pharmaceutical companies, although it is a very complex market. For those coming to…

Johnson&Johnson Romania In order to provide our readers with a general idea of the current state of the Romanian pharmaceutical and healthcare sectors, can you first of all elaborate on the key particularities of this market? Romania has been a member of the EU since 2009, is a potential member of the…

Nycomed Poland As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous year, but still managed to grow by 3,3% according to IMS data, which is in line with the market. This…

Quintiles Poland Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and intensive care departments of the Warsaw medical school. The team there was already conducting some medical research in the clinic.…

Servier China Servier was one of the first pharmaceutical companies to establish a presence in China back in 1979. How has Servier’s presence evolved alongside China’s huge transformations of the last decades? Indeed, we are very proud to be one of the pioneering foreign companies in China’s pharmaceutical market. The year was…

Ipsen Poland When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone performed in the same period? It is my personal privilege and pride to say that 2010 was an extremely good…